FFF Enterprises: BioSupply Trends Newsletter
Monday, Oct 17, 2016

GSK’s Shingles Vaccine Effective in Adults 70-Plus Years Old

 

In this Issue

•  IVIG/Albumin Supply Index
•  Open Market Pricing
•  New Products from FFF
•  Current Medicare
IVIG / SCIG Rates
•  Resources
•  Subscribe to IG Living and BioSupply Trends Quarterly
 

A randomized Phase III study (ZOE-70) of GlaxoSmithKline’s (GSK) investigational shingles vaccine, Shingrix, showed 90 percent efficacy in adults aged 70 years and older that is maintained for at least four years. [ read more ]

MMN Quality-of-Life Patient Survey Is Available

The Neuropathy Action Foundation (NAF) has released the results of its first international multifocal motor neuropathy (MMN) quality-of-life patient survey. [ read more ]

Researchers Call for Studies of IVIG for Treatment of ILD

Researchers at Harvard Medical School in Boston recently explored the use of intravenous immune globulin (IVIG) to treat interstitial lung disease (ILD) and found that while there is lack of evidence for its use, IVIG is increasingly being prescribed. They recommend that clinical trials be conducted to determine IVIG’s effectiveness in treating ILD. [ read more ]

Industry News

 
 

From Shire

The U.S. Food and Drug Administration has approved Shire’s CUVITRU (immune globulin subcutaneous [human] 20% solution) to treat adult and pediatric patients 2 years and older with primary immunodeficiency disease. [ read more ]

From Sandoz

Erelzi (etanercept-szzs), the first biosimilar etanercept, has been approved by the U.S. Food and Drug Administration for all indications included in the reference product’s label, including rheumatoid arthritis, plaque psoriasis, psoriatric arthritis, ankylosing spondylitis and polyarticular juvenile idiopathic arthritis. [ read more ]

From Amgen

The U.S. Food and Drug Administration has approved Amgen’s Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for the treatment of moderately to severe rheumatoid arthritis, active psoriatric arthritis, active ankylosing spondylitis, moderately to severely active Crohn’s disease, moderately to severely active ulcerative colitis and moderate to severe plaque psoriasis. [ read more ]

IVIG & Albumin Supply Index

 
 

What's New at FFF

SODIUM PHENYLACETATE AND SODIUM BENZOATE  
(Zydus Pharmaceuticals)

SODIUM PHENYLACETATE/SODIUM BENZOATE 10%/10% is a nitrogen-binding agent indicated as adjunctive therapy to treat acute hyperammonemia (too much ammonia in the blood) and associated encephalopathy in pediatric and adult patients with deficiencies in enzymes of the urea cycle. It is a concentrated solution that must be diluted before intravenous administration via a central venous catheter.

For more information about Sodium Phenylacetate/Sodium Benzoate, login to biosupply.fffenterprises.com
*Call for eligibility through your GPO affiliation.

CEFEPIME  (WG Critical Care)

Cefepime (intravenous infusion) is indicated for the treatment of several types of bacterial infections of the lungs, skin, abdomen and urinary tract.

For more information about Cefepime, login to biosupply.fffenterprises.com
*Call for eligibility through your GPO affiliation.

SOTRADECOL  (Mylan)

Sotradecol injection is indicated for the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves.

For more information about Sotradecol, go to biosupply.fffenterprises.com

ENTYVIO  (Takeda)

Entyvio (vedolizumab) is indicated for treatment of adults with 1) moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to or demonstrated dependence on corticosteroids to: induce and maintain clinical response or remission, improve endoscopic appearance of the mucosa or achieve corticosteroid-free remission; and 2) moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to or were intolerant to a TNF blocker or immunomodulator; or had an inadequate response with, were intolerant to or demonstrated dependence on corticosteroids to: achieve clinical response, clinical remission or corticosteroid-free remission.

For more information about Entyvio, go to biosupply.fffenterprises.com

ARIPIPRAZOLE  (Apotex)

Aripiprazole tablets are an atypical antipsychotic used to treat schizophrenia, bipolar disorder, major depressive disorder and irritability associated with autism.

For more information about Aripiprazole, login to biosupply.fffenterprises.com
*Call for eligibility through your GPO affiliation.

VERAPAMIL HCI INJECTION  (Exela Pharma Sciences)

Verapamil hydrochloride injectable (HCI) is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist) that works by relaxing the muscles of the heart and blood vessels. It is indicated for the treatment of supraventricular tachyarrhythmias, including 1) rapid conversion to sinus rhythm of paroxysmal supraventricular tachycardia, including those associated with accessory bypass tracts (Wolf-Parkinson-White [WPW] and Lown-Ganong-Levine [LGL] syndromes), and 2) temporary control of rapid ventricular rate in atrial flutter or atrial fibrillation, except when the atrial flutter and/or fibrillation are associated with accessory bypass tracts (Wolf-Parkinson-White [WPS] and Lown-Ganong-Levine [LGL] syndromes).

For more information about Verapamil HCI, go to biosupply.fffenterprises.com
*Call for eligibility through your GPO affiliation.

OMIDRIA  (Omeros)

Omidria is an alpha 1-adrenergic receptor agonist and nonselective cyclooxygenase inhibitor that is added to ophthalmic irrigation solution used during cataract surgery or intraocular lens replacement. It is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

For more information about Omidria, go to biosupply.fffenterprises.com

These products can be ordered from FFF Enterprise's BioSupply Online Ordering System or by calling
Wow! Customer Care at (800) 843-7477.

Current Medicare IVIG / SCIG Rates

Rates per gram are effective October 1, 2016, through December 31, 2016.

Product J Codes ASP + 6%
(before sequester)
ASP + 4.3%*
(after sequester)
IVIG
Bivigam J1556 $79.04 $77.77
Carimune NF J1566 $66.15 $65.09
Flebogamma J1572 $73.61 $72.43
Gammagard S/D J1566 $66.15 $65.09
Gammaplex J1557 $74.06 $72.88
Octagam J1568 $71.96 $70.81
Privigen J1459 $75.80 $74.58
SCIG
Hizentra J1559 $98.29 $96.71
HyQvia J1575 $127.44 $125.40
IVIG / SCIG
Gammagard Liquid J1569 $79.99 $78.71
Gammaked J1561 $77.16 $75.93
Gamunex-C J1561 $77.16 $75.93

*Reflects 2% sequestration reduction applied to 80% Medicare payment portion as required under Budget Control Act of 2011.

 

Resources

FFF customers may order the following complementary resources to help you with your practice:

•  IG Immune Globulin (Human)
•  Hyperimmune Globulins
•  Anti-Inhibitor, Factor VIIa & IX
•  Factor VIII & von Willebrand Factor
•  Seasonal Influenza Vaccine

Subscribe to IG Living

IG Living is the only magazine for the immune globulin (IG) community for patients who suffer from chronic illness and their caregivers.

Subscribe to BioSupply
Trends Quarterly

BioSupply Trends Quarterly magazine is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace.

Home | About | Advertise | Subscribe | Contact – ©2016 FFF Enterprises, Inc.
This email was sent by: %%Member_Busname%%, %%Member_Addr%% %%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%
Manage preferences: Privacy Policy, Update Profile, Unsubscribe.